Osteosarcoma developed in the period of maximal growth rate have inferior prognosis

Journal of Pediatric Hematology/Oncology

Volumn 30, Issue 6, 2008, Pages 419-424

  Lee, Jun Ah ^a   Kim, Min Suk ^a   Kim, Dong Ho ^a   Lim, Jung Sub ^a   Park, Kyung Duk ^a   Song, Won Seok ^a   Lee, Soo Yong ^a   Jeon, Dae Geun ^a  

^a Korea Cancer Center Hospital   (South Korea)

Author keywords

Children; Growth rate; Osteosarcoma; Prognosis

Indexed keywords

ADOLESCENT; ADULT; ARTICLE; CANCER CLASSIFICATION; CANCER DIAGNOSIS; CANCER LOCALIZATION; CANCER PATIENT; CANCER RECURRENCE; CANCER STAGING; CANCER SURGERY; CANCER SURVIVAL; CHILD; CHILD GROWTH; CLINICAL ASSESSMENT; CONTROLLED STUDY; FEMALE; FOLLOW UP; GROWTH RATE; HUMAN; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD REVIEW; METASTASIS; OSTEOSARCOMA; PRIORITY JOURNAL; PROGNOSIS; RETROSPECTIVE STUDY; TREATMENT OUTCOME; TREATMENT RESPONSE; BONE TUMOR; DISEASE FREE SURVIVAL; GROWTH; KAPLAN MEIER METHOD; MORTALITY; ORTHOPEDIC SURGERY; PATHOLOGY; PHYSIOLOGY; PRESCHOOL CHILD;

ANTINEOPLASTIC AGENT;

ADOLESCENT; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BONE NEOPLASMS; CHILD; CHILD, PRESCHOOL; DISEASE-FREE SURVIVAL; FEMALE; GROWTH; HUMANS; KAPLAN-MEIERS ESTIMATE; MALE; ORTHOPEDIC PROCEDURES; OSTEOSARCOMA; PROGNOSIS;

EID: 47549106493     PISSN: 10774114     EISSN: 15363678     Source Type: Journal    
DOI: 10.1097/MPH.0b013e318168e7dc     Document Type: Article

References (32)

1. van den Berg H, van der Lelie J. Acute lymphoblastic leukaemia in puberty and adolescence. Ann Oncol. 2000;11:1375-1379.
2. Silverman LB, Sallan SE. Newly diagnosed childhood acute lymphoblastic leukemia: update on prognostic factors and treatment. Curr Opin Hematol. 2003;10:290-296.
3. London WB, Castleberry RP, Matthay KK, et al. Evidence for an age cutoff greater than 365 days for neuroblastoma risk group stratification in the children's oncology group. J Clin Oncol. 2005;23: 6459-6465.
4. Maris JM, Hogarty MD, Bagatell R, et al. Neuroblastoma. Lancet. 2007;369:2106-2120.
5. McKenna RJ, Schwinn CP, Higinbotham NL. Osteogenic sarcoma in children. Calif Med. 1965;103:165-170.
6. Winkler K, Beron G, Kotz R, et al. Neoadjuvant chemotherapy for osteogenic sarcoma: results of a cooperative German/Austrian study. J Clin Oncol. 1984;2:617-624.
7. Ferrari S, Bertoni F, Mercuri M, et al. Predictive factors of diseasefree survival for non-metastatic osteosarcoma of the extremity: an analysis of 300 patients treated at the Rizzoli institute. Ann Oncol. 2001;12:1145-1150.
8. Hudson M, Jaffe MR, Jaffe N, et al. Pediatric osteosarcoma: therapeutic strategies, results, and prognostic factors derived from a 10-year experience. J Clin Oncol. 1990;8:1988-1997.
9. Bacci G, Longhi A, Bertoni F, et al. Primary high-grade osteosarcoma: comparison between preadolescent and older patients. J Pediatr Hematol Oncol. 2005;27:129-134.
10. Fuchs N, Bielack SS, Epler D, et al. Long-term results of the cooperative German-Austrian-Swiss osteosarcoma study group's protocol COSS-86 of intensive multidrug chemotherapy and surgery for osteosarcoma of the limbs. Ann Oncol. 1998;9:893-899.
11. Rogol AD, Roemmich JN, Clark PA. Growth at puberty. J Adolesc Health. 2002;31:192-200.
12. Greene FL, Page DL, Flemming FD, et al. American Joint Committee on Cancer: Cancer Staging Manual. New York, NY: Springer; 2002.
13. Rosen G, Marcove RC, Huvos AG, et al. Primary osteogenic sarcoma: eight-year experience with adjuvant chemotherapy. J Cancer Res Clin Oncol. 1983;106(Suppl):55-67.
14. Bieling P, Rehan N, Winkler P, et al. Tumor size and prognosis in aggressively treated osteosarcoma. J Clin Oncol. 1996;14:848-858.
15. Grovas A, Fremgen A, Rauck A, et al. The national cancer data base report on patterns of childhood cancers in the United States. Cancer. 1997;80:2321-2332.
16. Fraumeni JF Jr. Stature and malignant tumors of bone in childhood and adolescence. Cancer. 1967;20:967-973.
17. Longhi A, Pasini A, Cicognani A, et al. Height as a risk factor for osteosarcoma. J Pediatr Hematol Oncol. 2005;27:314-318.
18. Winkler K, Beron G, Delling G, et al. Neoadjuvant chemotherapy of osteosarcoma: results of a randomized cooperative trial (COSS-82) with salvage chemotherapy based on histological tumor response. J Clin Oncol. 1988;6:329-337.
19. Scranton PE Jr, DeCicco FA, Totten RS, et al. Prognostic factors in osteosarcoma. A review of 20 year's experience at the university of Pittsburgh health center hospitals. Cancer. 1975;36:2179-2191.
20. Rytting M, Pearson P, Raymond AK, et al. Osteosarcoma in preadolescent patients. Clin Orthop Relat Res. 2000;373:39-50.
21. Bacci G, Longhi A, Versari M, et al. Prognostic factors for osteosarcoma of the extremity treated with neoadjuvant chemotherapy: 15-year experience in 789 patients treated at a single institution. Cancer. 2006;106:1154-1161.
22. Meyers PA, Heller G, Healey J, et al. Chemotherapy for nonmetastatic osteogenic sarcoma: the memorial Sloan-Kettering experience. J Clin Oncol. 1992;10:5-15.
23. Buckley JD, Pendergrass TW, Buckley CM, et al. Epidemiology of osteosarcoma and Ewing's sarcoma in childhood: a study of 305 cases by the children's cancer group. Cancer. 1998;83:1440-1448.
24. Kaiser HE, Krenn M, Bodey B Jr, et al. Growth inhibitors in the treatment of malignant neoplasms. In Vivo. 2000;14:287-296.
25. Withrow SJ, Powers BE, Straw RC, et al. Comparative aspects of osteosarcoma dog versus man. Clin Orthop Relat Res. 1991;270: 159-168.
26. Cotterill SJ, Wright CM, Pearce MS, et al. Stature of young people with malignant bone tumors. Pediatr Blood Cancer. 2004;42: 59-63.
27. Clark PA, Rogol AD. Growth hormones and sex steroid interactions at puberty. Endocrinol Metab Clin North Am. 1996;25: 665-681.
28. Yu H, Rohan T. Role of the insulin-like growth factor family in cancer development and progression. J Natl Cancer Inst. 2000;92: 1472-1489.
29. Valentinis B, Baserga R. IGF-I receptor signalling in transformation and differentiation. Mol Pathol. 2001;54:133-137.
30. Beech DJ, Perer E, Helms J, et al. Insulin-like growth factor-I receptor activation blocks doxorubicin cytotoxicity in sarcoma cells. Oncol Rep. 2003;10:181-184.
31. Frank GR. Role of estrogen and androgen in pubertal skeletal physiology. Med Pediatr Oncol. 2003;41:217-221.
32. Krailo M, Ertel I, Makley J, et al. A randomized study comparing high-dose methotrexate with moderate-dose methotrexate as components of adjuvant chemotherapy in childhood nonmetastatic osteosarcoma: a report from the childrens cancer study group. Med Pediatr Oncol. 1987;15:69-77.